

MEDICAL TECHNOLOGY M&A PULSE

FIRST QUARTER 2022



Q1'22

INSIDE THIS ISSUE

Trends in Medical Technology	PAGE 4
Medical Technology M&A Activity	PAGES 5-9
2022 Q1 Public Market Summary	PAGES 10-13
Venture Capital Activity Overview	PAGE 14

PMCF Medical Technology Team

ABOUT PMCF

P&M Corporate Finance ("PMCF"), a U.S. registered broker/dealer, is an investment bank focused exclusively on middle market transactions with professionals in Chicago, Detroit, Denver, and across the globe through Corporate Finance International partners. Offering a depth of advisory services, PMCF helps clients worldwide meet their sale, acquisition, financing, and strategic growth objectives. Additional information on PMCF can be found by visiting our website, pmcf.com.

INVESTMENT BANKING SERVICES:

- Mergers & Acquisitions
- Carve-outs & Divestitures
- Strategic Assessments
- Transaction Readiness Planning
- Capital Raising



BRYAN HUGHES
Managing Director
312.602.3636
Bryan.Hughes@pmcf.com



MATT JAMISON
Managing Director
312.602.3583
Matt.Jamison@pmcf.com



MIKE BROOKS
Vice President
312.602-3644
Mike.Brooks@pmcf.com



JAKE STESLICKI
Associate
248.603.5369
Jake.Steslicki@pmcf.com

Medical Technology Industry Expertise

In the medical technology sector, it takes a highly focused approach to execute a transaction efficiently. And it requires the constant monitoring of new procedures, technology and product development, and overall market trends. At PMCF, our Medical Technology team brings this dedication and market knowledge to every transaction. Our transaction expertise in the medical device, bio-pharmaceutical, and healthcare sectors, combined with industry relationships and a proprietary healthcare consulting service offering, afford us a unique perspective in the industry.

Medical Devices	Contract Research	Clinical Services	Therapeutics
Healthcare	Contract Manufacturing	Behavioral Health	Managed Care
Drug Delivery	Bio-Pharmaceutical	Specialty Pharmacy	Specialty Services

SELECT RECENT PMCF MEDICAL TECHNOLOGY TRANSACTIONS



2022 Q1 Market Summary


Q1 2022: A TUMULTUOUS START TO A CRITICAL YEAR

- 2022 started much as 2020 and 2021 had ended, with the world in the midst of a new COVID-19 outbreak, this one tied to the much milder Omicron variant. Fortunately, this variant's emergence as the dominant strain of COVID improved the global health situation enough that countries worldwide began lifting restrictions and returning life to something resembling pre-pandemic normal.
- On top of COVID, the first quarter was defined by the outbreak of armed conflict between Russia and Ukraine, which has had major impacts on the global supply chain for key natural resources such as gas and wheat. Equity markets reflected this negative sentiment, with the S&P 500 and Dow Jones both down during the quarter.
- M&A transaction volume was down from the record pace of 2021's first quarter, though still at a very healthy level, exceeding 2018 and 2020's first quarter marks, and down slightly from 2019's. Valuation metrics remained advantageous for sellers, with both mean and median TEV / EBITDA multiples up from 2021-year end levels.
- The 4 tracked medical subsector indices all outperformed the benchmark S&P 500 Growth Index, which was down 9.5%, and three of the medical indices outperformed the Dow Jones Industrial Average which was down 5.2%.

2022 Q1 NOTABLE EVENTS TIMELINE

- January 10, 2022 | 40th Annual J.P. Morgan Health Care Conference Kicks Off in San Francisco, CA
- January 18, 2022 | Microsoft Announces Intent to Acquire Activision Blizzard, Largest Tech Acquisition in History
- January 28, 2022 | Worldwide COVID-19 Vaccinations Exceed 10 Billion
- February 4, 2022 | 2022 Winter Olympics Begin in Beijing, China
- February 16, 2022 | Dow Drops More Than 600 Points Over Russia-Ukraine Concerns
- February 24, 2022 | Russia Invades Ukraine, Significantly Escalating Clashes in the Region
- February 26, 2022 | E.U., U.S., and Allies Commit to Removing Russian Banks from SWIFT Payment System, Fueling Financial Crisis in Russia
- March 7, 2022 | Global COVID-19 Death Toll Surpasses 6 Million
- March 16, 2022 | Federal Open Market Committee Raises Federal Funds Rate by 25 Basis Points
- March 30, 2022 | UnitedHealth Group Subsidiary Optum Agrees to Acquire LHC Group for \$5.4B, Largest Healthcare M&A Deal of 2022 to Date


PMCF MEDICAL TECHNOLOGY INDICES PERFORMANCE



Sources: Capital IQ, PitchBook, Company Reports, Fraser


Trends in Medical Technology

U.S. PERSONAL HEALTH CARE SERVICES EXPENDITURES (\$B)




- Disposable personal income refers to the amount U.S. residents have left to spend after paying taxes. It has historically been relatively stable and increasing, though it has alternately spiked and dipped since the pandemic, in part due to temporary economic stimulus packages.
- For various segments of the healthcare industry, spending on healthcare is correlated with disposable income, making it a valuable macroeconomic indicator. Currently, total disposable income is \$15.3B, down from \$17.3B a year ago.

U.S. MEDICAL INSTRUMENT & SUPPLY MANUFACTURING (\$B)



- The Medical Device, Instrument, Technology, and Supply industries in the United States together constitute one of the most critical and advanced industries in the world, leveraging advances in biotechnology, materials science, robotics, and therapeutics.
- Industry experts forecast growth of 3.0% in 2022 to over \$90B in total revenue, followed by growth of 1.0% - 1.6% during the remainder of the projected period. Figures are inflation adjusted to 2021.

MEDICAL EQUIPMENT & SUPPLY PRODUCER PRICE INDEX (PPI)



- As in the broader U.S. economy, medical equipment producer costs have dramatically risen since mid-2021. The Bureau of Labor Statistics provides a Producer Price Index (PPI) that measures the average change in selling price of domestic output. The Medical Equipment & Supply PPI value serves as a broad proxy for Medical industry costs.
- The PPI is based on a 2003 baseline equal to 100. Currently the index is at 125.4, up from 123.2 in Q4 2021.

Sources: PMCF Research, FRED, US Census Bureau, IBIS

Medical Technology M&A Activity

Medical Equipment

Fresenius Kabi acquires Ivenix, Inc.

March 2022 — Fresenius Kabi, a subsidiary of Fresenius SE & Co. (XTRA:FRE), announced a definitive agreement to acquire Ivenix. Ivenix develops intravenous (IV) infusion system solutions, including an IV smart pump that eliminates air from the fluid bag, and IV lines that reduce air in line arms. These systems were designed from the ground up and bring infusion technology into the digital age. Total transaction consideration is valued at up to \$240 million, based on the achievement of milestone payments tied to commercial and operating targets. Fresenius Kabi is a global health care leader specializing in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The transaction aims to establish Fresenius Kabi as a leader in the infusion market. Jorgen B. Hansen, Ivenix's Chief Executive Officer said "We're very pleased to partner with Fresenius Kabi, a leading global health care company. Together, we intend to transform the standard of care for North American health care providers and patients by providing the highest level of safe and effective integrated infusion care."

Therapeutic Device

CooperCompanies (NYSE:COO) acquires Cook Medical's Reproductive Health Business

February 2022 — Cook Medical announced a definitive agreement to sell the entirety of Cook's Reproductive Health business, which falls within the Cook's MedSurg division. For more than 40 years, Cook has had a focus on Reproductive Health, successfully developing products for obstetrics and gynecology, In Vitro Fertilization (IVF) and Assisted Reproductive Technology (ART). Transaction consideration consists of \$675 million at close, plus an additional \$200 million paid in 4 \$50 million annual installments. The \$875 million in total consideration values the business at 5.5 times trailing twelve months revenue. "Our history with reproductive health has been full of innovations to help patients fulfill their dreams of having a family," said D.J. Sirota, senior vice president of Cook Medical's MedSurg specialty. "This agreement represents more than a simple transaction; it is a commitment to offer a more complete range of solutions to customers and patients around the world. CooperSurgical is uniquely positioned to combine Cook's reproductive health portfolio with their resources and plans to significantly invest in this product portfolio."

Consumable & Disposable

TEAM Technologies acquires iiMED Medical Solutions


January 2022 — TEAM Technologies, Inc., a North American engineering solutions and specialty manufacturer serving healthcare end markets backed by Clearlake Capital Group announced that it has acquired iiMED Medical Solutions from ACON Investments. iiMED is a nearshore specialty manufacturer of FDA Class I & II consumable medical devices that partners with healthcare OEMs from design to manufacturing devices for patient monitoring, wound care, and compression therapy treatments. TEAM Technologies has been highly acquisitive since being backed by Clearlake in 2018, completing 4 acquisitions since. The combination with iiMED enhances TEAM's technical capabilities and establishes an attractive nearshore presence to better support customers. Financial terms of this transaction were not disclosed. "We are thrilled to welcome iiMED's customer partners and talented employees to the TEAM family. We have been impressed with iiMED's rapid growth and deep expertise across an array of specialty manufacturing solutions, and we look forward to working with the iiMED team to grow our combined business to better serve our healthcare customers," said Marshall White, President and CEO of TEAM.

M&A Activity Roundup


TRENDS IN MEDICAL TECHNOLOGY M&A

- M&A transaction volume during the first quarter of 2022 was down 36% from 2021's frenzied Q1 pace. The quarter's 131 announced transactions was in line with the 2018 - 2020 Q1 average of 133 transactions, highlighting the still robust level of market activity despite the decline from 2021. As in 2021, Service and Equipment were the most active sectors, while Consumable / Disposable had the largest relative decline in volume year-over-year.
- Financial terms remained attractive for sellers during Q1, with both mean and median TEV / EBITDA multiples increasing over 2021-year end levels, and revenue multiples doing the same. Mean and median transaction levels were both down slightly when compared to full 2021 data, though mean value was up compared to just 2021's first quarter. 29% of announced transactions disclosed transaction value, a similar percentage as in the first quarter of 2021.

TRANSACTIONS BY PRODUCT SEGMENT - Q1 2022



MEDICAL DEVICE M&A TRANSACTION METRICS



Period	Mean/Median	Transaction Value (\$MM)	TEV/REV	TEV/EBITDA
2022 Q1	Mean	\$517.9	15.31x	50.80x
2022 Q1	Median	\$26.7	4.20x	18.05x
2021 Q1	Mean	\$476.5	7.02x	14.43x
2021 Q1	Median	\$64.0	4.42x	12.23x
2021	Mean	\$634.0	6.11x	17.60x
2021	Median	\$60.7	3.71x	14.54x
2020	Mean	\$416.7	5.28x	30.54x
2020	Median	\$24.3	2.40x	13.57x
2019	Mean	\$762.3	6.76x	18.06x
2019	Median	\$24.8	2.83x	14.08x


Sources: Capital IQ, PitchBook, Company Reports, PMCF

Medical Equipment M&A


TRENDS IN MEDICAL EQUIPMENT M&A

- Like much of the broader M&A market, Q1 2022 saw decreased volumes from Q1 2021's high water mark. The quarter was still a strong performer however, with volume up meaningfully from both 2019 and 2020's first three months.
- Flipping the script from 2021, private acquirers were more active than their public counterparts, comprising 57% of total announced transactions. Public buyers made up the second largest segment, while private equity groups were third.
- Looking at transactions by cross-border classification, much of the decline in Q1 volume year-over-year can be linked to a pullback in U.S. based seller activity. Of the 16-transaction decrease in volume, 11 relate to reduced activity in U.S. seller categories versus 5 from international buyers.
- As has recently been the case, Furniture/Equipment was the leading end market within the broader Medical Equipment category. The Monitor end market was a close second and appears to be on pace for a meaningful increase over 2021 volume, with 7 transactions announced during the quarter compared to 16 in all of 2021.

FINANCIAL VS. STRATEGIC BUYER MEDICAL EQUIPMENT



MEDICAL EQUIPMENT TRANSACTIONS BY BUYER TYPE



TRANSACTIONS BY END MARKET

End Market	2019	2020	2021	21 Q1	22 Q1
Acute Care	1	4	2	-	-
Aesthetic	2	-	1	-	2
Cardiovascular	5	3	4	1	1
Drug Delivery	1	5	8	4	-
Furniture/Equipment	37	25	37	13	8
Home Health	10	9	11	1	2
Hospital Care	7	21	19	8	5
Infection Control	5	1	2	-	-
IVD	-	1	6	1	-
Monitor	8	12	16	3	7
Neurovascular	2	2	2	-	-
Ophthalmology	7	6	8	1	2
Ortho	1	-	6	4	-
Other	19	11	10	-	-
Respiratory	7	6	12	1	1
Support	9	6	11	2	-
Surgical	15	17	16	7	2
Total	136	129	171	46	30

CROSS BORDER TRANSACTION TRENDS

Seller-to-Buyer	2019	2020	2021	21 Q1	22 Q1
Int'l-to-Int'l	66	57	62	16	14
U.S.-to-Int'l	11	12	16	8	4
U.S.-to-U.S.	48	46	76	16	9
Int'l-to-U.S.	11	14	17	6	3
Total	136	129	171	46	30


Sources: Capital IQ, PitchBook, Company Reports, PMCF

Therapeutic Device M&A


TRENDS IN THERAPEUTIC DEVICE M&A

- Therapeutic Device first quarter 2022 M&A activity was down 36.8% compared to the same period in 2021, though exactly in line with the average of 2019 and 2020 activity. Financial buyers made up 17% of transactions compared to 18% a year ago, and 37% in 2021's fourth quarter.
- Public buyers are generally the most active segment in the Therapeutic Device space, and that trend looks to be continuing in 2022. After making up 56.7% of acquisitions in the space in 2021, they made up an even 50.0% of transactions in the first quarter of the new year.
- The diversified Other end market again saw the most transactions announced during the first quarter, with Orthopedic, Ophthalmology, and Cardiovascular tied for second. These four were also the top end markets in 2019 – 2021.
- Purely domestic and purely international transactions were almost even in terms of volume. Of the 24 total transactions in the Therapeutic Device sector, 16 involved at least one U.S. based party, with the 66.7% up from the 47.4% a year ago.

FINANCIAL VS. STRATEGIC BUYER THERAPEUTIC DEVICE



THERAPEUTIC DEVICE TRANSACTIONS BY BUYER TYPE



TRANSACTIONS BY END MARKET

End Market	2019	2020	2021	21 Q1	22 Q1
Acute Care	6	3	3	1	1
Aesthetic	-	-	1	-	-
Cardiovascular	7	10	18	4	4
Drug Delivery	-	2	-	-	-
Furniture/Equipment	1	3	2	2	-
Home Health	2	5	7	3	-
Hospital Care	-	-	1	-	-
Infection Control	3	-	2	-	-
IVD	3	1	1	1	-
Monitor	-	2	-	-	-
Neurovascular	5	1	4	3	1
Ophthalmology	13	7	15	4	4
Ortho	33	37	28	7	4
Other	23	36	45	11	6
Respiratory	3	3	8	1	2
Support	1	2	5	-	1
Surgical	2	5	1	1	1
Total	102	117	141	38	24

CROSS BORDER TRANSACTION TRENDS

Seller-to-Buyer	2019	2020	2021	21 Q1	22 Q1
Int'l-to-Int'l	34	47	61	20	8
U.S.-to-Int'l	6	10	10	1	2
U.S.-to-U.S.	51	46	59	14	9
Int'l-to-U.S.	11	14	11	3	5
Total	102	117	141	38	24


Sources: Capital IQ, PitchBook, Company Reports, PMCF

Consumable & Disposable M&A


TRENDS IN CONSUMABLE & DISPOSABLE M&A

- After the flurry of activity in 2021, Consumable & Disposable saw one of the largest slowdowns of any sector during 2022's first quarter. Announced transaction count was the lowest it has been for any first quarter in the last five years, with both strategic and financial activity down.
- Private equity buyers were involved in a much larger share of transactions in 2022 Q1 than in 2021, comprising 57.1% of acquirers vs. 32.9%. This increase in proportion mostly came at the expense of public acquirers, who saw their share of transaction activity decline from 50.6% to 28.6%.
- During the quarter there were no U.S. involved cross border transactions, likely a function of the low level of activity in the Consumable & Disposable sector as a whole.
- Infection Control was again the most active end market, continuing a trend started in 2020 with the onset of the pandemic. Surgical was the next most common end market, while Hospital Care saw the largest decline in activity year-over-year.

FINANCIAL VS. STRATEGIC BUYER CONSUMABLE & DISP.



CONSUMABLE & DISP. TRANSACTIONS BY BUYER TYPE



TRANSACTIONS BY END MARKET

End Market	2019	2020	2021	21 Q1	22 Q1
Acute Care	8	8	9	3	-
Aesthetic	2	-	1	-	-
Cardiovascular	2	-	-	-	-
Drug Delivery	5	8	4	1	-
Furniture/Equipment	1	-	1	-	-
Home Health	4	2	2	2	-
Hospital Care	9	6	14	5	-
Infection Control	2	18	27	6	4
IVD	5	1	3	2	-
Monitor	-	-	1	-	-
Neurovascular	-	-	-	-	-
Ophthalmology	3	1	1	1	-
Ortho	-	1	-	-	-
Other	22	11	4	-	1
Respiratory	2	2	-	-	-
Support	6	3	6	-	-
Surgical	10	-	6	5	2
Total	81	61	79	25	7

CROSS BORDER TRANSACTION TRENDS

Seller-to-Buyer	2019	2020	2021	21 Q1	22 Q1
Int'l-to-Int'l	42	35	41	12	3
U.S.-to-Int'l	9	4	8	2	-
U.S.-to-U.S.	25	21	23	7	4
Int'l-to-U.S.	5	1	7	4	-
Total	81	61	79	25	7

Sources: Capital IQ, PitchBook, Company Reports, PMCF

Diversified Medical Device Public Comparables

PUBLIC DIVERSIFIED MEDICAL DEVICE COMPANY COMMENTARY


- “So Ukraine and Russia, it definitely poses some incremental challenges as far as global supply chain and logistics are concerned... clearly, the price of oil is directly related to freight costs and it’s also indirectly related to other input costs like resin, for example.” – James Saccaro, Baxter Executive VP & CFO
- “As market demand for all COVID-19 vaccines is currently challenged by global supply surplus and vaccine hesitancy in developing markets, we have made the decision to suspend guidance for sales of our COVID-19 vaccine. This will enable investors to focus on the performance of our core businesses, which drive the current and future value for investors.” – Joseph Wolk, Johnson & Johnson Executive VP & CFO

DIVERSIFIED MEDICAL DEVICE PUBLIC COMPARABLES SUMMARY


Company Name	LTM as of	Cash (\$MM)	Debt (\$MM)	Market Cap (\$MM)	TEV (\$MM)	TEV/REV	TEV/EBITDA	P/E
Abbott Laboratories	3/31/2022	10,249	19,251	208,726	217,950	5.1x	16.6x	30.0x
Baxter International Inc.	3/31/2022	2,294	17,682	39,018	54,450	4.3x	17.3x	30.6x
Becton, Dickinson and Company	12/31/2021	1,911	17,424	75,749	91,264	4.6x	16.9x	46.2x
Boston Scientific Corporation	3/31/2022	1,925	9,525	63,310	70,910	6.0x	22.2x	64.2x
Intuitive Surgical, Inc.	3/31/2022	3,995	0	108,362	104,421	18.3x	48.5x	64.7x
Johnson & Johnson	4/3/2022	30,388	33,148	466,047	468,807	5.0x	14.2x	22.7x
Medtronic plc	1/28/2022	11,221	25,155	148,844	162,949	5.1x	16.5x	30.6x
Smith & Nephew plc	12/31/2021	1,290	3,339	14,002	16,051	3.2x	13.3x	27.7x
Stryker Corporation	3/31/2022	1,530	14,598	100,978	114,046	6.5x	23.2x	51.3x
High		30,388	33,148	466,047	468,807	18.3x	48.5x	64.7x
Mean		7,200	15,569	136,115	144,539	6.4x	21.0x	40.9x
Median		2,294	17,424	100,978	104,421	5.1x	16.9x	30.6x
Low		1,290	0	14,002	16,051	3.2x	13.3x	22.7x

As of March 31, 2022

DIVERSIFIED MEDICAL DEVICE MULTIPLES



DIVERSIFIED MEDICAL DEVICE INDEX



EV/EBITDA multiples for the Diversified Medical Device (“DMD”) sector finished the first quarter of 2022 slightly below year end levels in 2021, 21.0x vs 22.0x. Compared to the first quarter a year ago the decline was more severe, with EBITDA multiples down 19.4%. There were two companies in the DMD sector with a higher multiple at the end of 2022 Q1 than 2021 Q1, Baxter International, and Becton, Dickinson and Company. Medtronic saw the largest percentage decline in EBITDA multiple, dropping from 27.7x to 16.5x. Average Revenue multiples had a milder decline year-over-year, down 8.4%. Intuitive continues to lead the sector in revenue multiples, while the next closest is Stryker at 6.5x.

The PMCF DMD index finished the first quarter down 2.9% on the year. While a negative start to the year, this far surpassed the performance of the benchmark S&P 500 Growth Index which was down 9.5% during the same period.

Sources: Capital IQ, PitchBook, Company Reports, PMCF

Orthopedic Public Comparables

PUBLIC ORTHOPEDIC MEDICAL DEVICE COMPANY COMMENTARY


- “One of the other things that we’re super excited about is for years, minimally invasive surgery was relegated to the hospital. And what we’re seeing is we’re seeing a 60-minute, 360-degree fusion in an outpatient ASC setting. And so now you’re seeing reconstructive minimally invasive spine surgery done in the outpatient setting. And what avails that is automated neurophysiology.” – Patrick Miles, Alphatec Executive Chairman, CEO, & President
- “There are some great trends that you see...in terms of aging population. People want to become -- remain more active over time, the continued quest for innovation that creates better outcomes and better lives for patients.” – Matthew Trerotola, Enovis CEO & Director

ORTHOPEDIC MEDICAL DEVICE PUBLIC COMPARABLES SUMMARY


Company Name	LTM as of	Cash (\$MM)	Debt (\$MM)	Market Cap (\$MM)	TEV (\$MM)	TEV/REV	TEV/EBITDA	P/E
Alphatec Holdings, Inc.	12/31/2021	187	355	1,148	1,339	5.5x	NM	NM
Enovis Corporation	12/31/2021	719	2,275	6,419	8,019	2.1x	12.5x	66.3x
Globus Medical, Inc.	12/31/2021	443	5	7,493	7,055	6.8x	24.2x	51.2x
NuVasive, Inc.	12/31/2021	246	1,009	2,945	3,708	3.3x	17.6x	NM
Orthofix Medical Inc.	12/31/2021	88	26	649	587	1.3x	16.2x	NM
Smith & Nephew plc	12/31/2021	1,290	3,339	14,002	16,051	3.2x	13.3x	27.7x
Stryker Corporation	3/31/2022	1,530	14,598	100,978	114,046	6.5x	23.2x	51.3x
Surgalign Holdings, Inc.	12/31/2021	51	11	47	7	0.1x	NM	NM
Zimmer Biomet Holdings, Inc.	3/31/2022	495	7,372	26,772	33,655	4.3x	13.6x	67.0x
High		1,530	14,598	100,978	114,046	6.8x	24.2x	67.0x
Mean		561	3,221	17,828	20,496	3.7x	17.2x	52.7x
Median		443	1,009	6,419	7,055	3.3x	16.2x	51.3x
Low		51	5	47	7	0.1x	12.5x	27.7x

As of March 31, 2022

ORTHOPEDIC MEDICAL DEVICE MULTIPLES



ORTHOPEDIC MEDICAL DEVICE INDEX



Like the other PMCF tracked sectors, both revenue and EBITDA multiples in the Orthopedic Medical Device were down from 2021 Q1 peaks at the end of the 2022 first quarter, with revenue down 25.2% and EBITDA down 25.6%. Orthofix experienced the steepest decline, down 49.4% from 32.1x to 16.1x. Smith & Nephew and Zimmer Biomet followed with the next two largest decreases. Despite the decline year-over-year, the first quarter was positive compared to the end of 2021 on the EBITDA multiple side, up from 16.6x to 17.2x, while revenue multiples declined very slightly from 3.8x to 3.7x.

PMCF’s OMD index was down slightly during the quarter, recovering from being down as much as 9.6% on March 14th before rallying to close the quarter down just 1.9%.

Sources: Capital IQ, PitchBook, Company Reports, PMCF

Cardiovascular Public Comparables

PUBLIC CARDIOVASCULAR MEDICAL DEVICE COMPANY COMMENTARY


- “Think of what will happen when a choice is presented to a patient that says, you can get this valve and it will be your valve for life. And there is no blood testing, there is no diet restriction, you just take this pill. We believe that will be very compelling to people.”– John Davis, Artivion Senior Vice President of Global Sales & Marketing
- “What we’re seeing is the field is moving toward less invasive treatments for sometimes very high-risk patients that surgeons either find challenging or for patients who would rather not have surgery. And this can be done for a patient who needs multiple blockages fixed, just like in surgery, by implanting the Impella heart pump, which supplies blood to the heart and the rest of the body while the procedure is being done.” – Charles Simonton, Abiomed, VP & Chief Medical Officer

CARDIOVASCULAR MEDICAL DEVICE PUBLIC COMPARABLES SUMMARY


Company Name	LTM as of	Cash (\$MM)	Debt (\$MM)	Market Cap (\$MM)	TEV (\$MM)	TEV/REV	TEV/EBITDA	P/E
Abiomed, Inc.	3/31/2022	759	13	15,077	14,332	14.1x	48.1x	113.9x
AngioDynamics, Inc.	2/28/2022	24	33	834	843	2.7x	69.8x	NM
Cardiovascular Systems, Inc.	3/31/2022	172	20	917	765	3.0x	NM	NM
Artivion, Inc.	12/31/2021	55	362	858	1,165	3.9x	35.5x	0.0x
Edwards Lifesciences Corporation	3/31/2022	1,496	688	73,141	72,334	13.8x	41.2x	49.5x
LeMaitre Vascular, Inc.	3/31/2022	71	16	1,019	964	6.2x	19.2x	37.2x
Medtronic plc	1/28/2022	11,221	25,155	148,844	162,949	5.1x	16.5x	30.6x
Merit Medical Systems, Inc.	3/31/2022	54	323	3,763	4,032	3.7x	19.8x	79.2x
Terumo Corporation	12/31/2021	1,796	2,196	23,194	23,594	4.2x	16.5x	31.2x
High		11,221	25,155	148,844	162,949	14.1x	69.8x	113.9x
Mean		1,739	3,201	29,739	31,220	6.3x	33.3x	48.8x
Median		172	323	3,763	4,032	4.2x	27.7x	37.2x
Low		24	13	834	765	2.7x	16.5x	0.0x

As of March 31, 2022

CARDIOVASCULAR MEDICAL DEVICE MULTIPLES



CARDIOVASCULAR MEDICAL DEVICE INDEX



Cardiovascular Medical Devices multiples finished the first quarter just below their 2020 and 2021 year end levels, 33.3x vs. 35.2x and 35.0x respectively. This was a large drop from the frothy heights of Q1 2021, when they finished at 39.8x. Revenue multiples had a more pronounced decline, down to 6.3x, though still a very robust valuation when compared to the pre-pandemic 2019 year end. AngioDynamics remains the outlier in the sector, trading at 69.8x EBITDA at year end, down from 98.0x a year ago. Abiomed and Edwards Lifesciences also retained premium valuations relative to the sector, trading at 48.1x and 41.2x.

The CMD index had a challenging quarter, at one point closing down as much as 12.4%, before ultimately closing the quarter down 3.9%, out performing the Diagnostic index but trailing the Orthopedic and Diversified indices.

Sources: Capital IQ, PitchBook, Company Reports, PMCF

Diversified Diagnostic Public Comparables

PUBLIC DIVERSIFIED DIAGNOSTIC COMPANY COMMENTARY


- “In terms of academic and government, you’re seeing good level of investment across the world in supporting academic research. I actually think the pandemic actually highlighted the importance of fundamental understanding of disease and investments there. Health care and diagnostics largely have returned to the pre-pandemic levels in terms of activities and demographics, favorable -- favored to good growth.” – Marc Casper, Thermo Fisher Scientific, Chairman, President, & CEO
- “For Roche, the future lies very much in personalized health care. Advancing digitalization plays a key role in this regard...By combining and analyzing genomic data and data from clinical practice, we can identify completely new approaches.” – Christoph Franz, Roche, Independent Non-Executive Chairman

DIVERSIFIED DIAGNOSTIC PUBLIC COMPARABLES SUMMARY


Company Name	LTM as of	Cash (\$MM)	Debt (\$MM)	Market Cap (\$MM)	TEV (\$MM)	TEV/REV	TEV/EBITDA	P/E
Abbott Laboratories	3/31/2022	10,249	19,251	208,726	217,950	5.1x	16.6x	30.0x
Becton, Dickinson and Co.	12/31/2021	1,911	17,424	75,749	91,264	4.6x	16.9x	46.2x
Danaher Corporation	12/31/2021	2,586	23,272	209,993	233,957	7.9x	22.0x	34.5x
Hologic, Inc.	3/26/2022	2,296	3,093	19,204	20,001	3.8x	7.8x	11.6x
Laboratory Corporation of America	3/31/2022	1,234	6,323	24,567	29,677	1.8x	6.8x	10.8x
Novartis AG	3/31/2022	18,721	31,341	197,188	209,972	3.8x	6.2x	8.4x
Quest Diagnostics Incorporated	3/31/2022	712	4,663	16,349	20,416	1.9x	6.3x	8.8x
Roche Holding AG	12/31/2021	14,297	35,708	322,971	348,612	4.9x	13.0x	22.6x
Thermo Fisher Scientific Inc.	12/31/2021	4,477	36,339	231,057	263,103	6.7x	20.0x	30.4x
High		18,721	36,339	322,971	348,612	7.9x	22.0x	46.2x
Mean		6,276	19,713	145,089	159,439	4.5x	12.8x	22.6x
Median		2,586	19,251	197,188	209,972	4.6x	13.0x	22.6x
Low		712	3,093	16,349	20,001	1.8x	6.2x	8.4x

As of March 31, 2022

DIVERSIFIED DIAGNOSTIC MULTIPLES



DIVERSIFIED DIAGNOSTIC INDEX



EV/EBITDA multiples within the Diversified Diagnostic (“DD”) industry remained behind those of PMCF’s other tracked medical sectors, closing the quarter at 12.8x. Roche had the strongest Q1 in terms of EBITDA multiples, up 17.1%, while Thermo Fisher led the way in revenue multiple growth, up 12.6%. Danaher retained the distinction of having the highest EBITDA and revenue multiples in the cohort, at 22.0x and 7.9x respectively. LabCorp had the lowest EBITDA multiple at 6.2x, while Johnson & Johnson had the lowest revenue multiple at 1.8x.

The DD Index was the worst performing of the four tracked PMCF sectors, down 6.1% on the year at the end of the first quarter. Despite its poor performance, it still outperformed the benchmark S&P 500 Growth index which was down 9.5%, and showed strong momentum to close the quarter, rallying from 12.4% down over the last 15 trading days.

Sources: Capital IQ, PitchBook, Company Reports, PMCF

2022 Venture Capital Activity Overview


2021 may have marked the peak for a historically strong run of U.S. venture capital activity, with the record setting year far outpacing even 2020's previous record highs for both deal count and value. While a very strong start to the year in its own right, 2022's first quarter was closer to 2020 than 2021 in terms of performance. Annualizing first quarter performance, Q1 deal value was down 17.3%, from \$342.2B in 2021 to \$282.9B. This still represented a 70.6% increase over 2020 deal value, illustrating the extent to which 2021 was an outlier. Based on year-to-date activity, the trend towards late stage companies in the VC world looks to be continuing, with 34.0% of deals involving a late stage company, the highest the figure has been since 2008. Likewise, activity at the angel & seed round dropped to 36.2% of deals, the lowest level since 2009.

It remains to be seen if this trend will persist during the remainder of 2022. Against the broader specter of the public market uncertainty, the VC backed IPO is no longer the sure success it looked like for much of 2021. As of mid-March 2022, the top 10 VC backed IPOs from 2021 were down ~20% - 70%. This valuation slide has slowed the number of IPOs in 2022 and may ultimately reduce late stage VC investment activity given the potential challenges in achieving a successful exit. Historically however, VC deal activity has lagged public market sentiment, meaning any significant downward pressures may not be realized for some time.


While deal count slowed slightly, valuations showed no signs of weakening in 2022, with investors chasing premium assets. Median pre-value at all four deal stages increased significantly, from 14.3% for late stage all the way up to 77.3% for angel. Over the last 5 years valuations at all stages have at least doubled, averaging 2.9x growth across stages.

Focusing in on healthcare, all three subsectors experienced declines in deal volume. Pharma & Biotech had the most significant decline, down 25.4%, while HC Devices & Supplies was down 16.8% and HC Services & Systems was down 14.8%. Despite these declines in volume VC funds closed on over \$70B in capital in Q1, leading to record high levels of dry powder and number of active investors in the market.


VC INVESTMENTS IN MEDICAL SECTORS



MEDIAN PRE-MONEY VALUATION BY ROUND



DEAL COUNT BY ROUND



Angel/Seed: The company has a concept or product under development, but is likely not fully operational. Typically in existence less than 18 months.

Early: The company has a product or service in testing or pilot production. In some cases, the product may be commercially available. May or may not be generating revenues. Typically in business less than three years.

Later: Product or service is widely available. Company is generating ongoing revenue; potentially positive cash flow. More likely to be, but not necessarily, profitable.

Sources: Capital IQ, PitchBook, NVCA, PMCF

PMCF's Unique Approach to M&A Advisory

PMCF's M&A advisory and investment banking services are designed to provide company shareholders with a trusted advisor to oversee all transaction related aspects of a company sale or strategic acquisition. Our service levels, industry expertise in medical technology, and approach to managing transactions positions us favorably against a traditional investment banker. See below for some examples of our differentiation:

- Differentiated approach via senior banker leadership and direct involvement through every step of the transaction providing a consistent and highly experienced point of contact
- One of the largest, most active investment banking boutiques with a focus on specialty niche businesses
- Proven positioning and marketing processes to obtain premium valuations in company sales
- Tailored sale process provides for extensive upfront preparation, detailed company review and identification of any potential issues in advance, and buyer evaluation/diligence ensuring the right fit
- Unique sale planning approach that helps shareholders best prepare for a future sale whether its six months or several years
- Long-term and client first approach allows PMCF to provide unbiased advice



Two-time winner, Boutique Investment Banking Firm of the Year
by M&A Advisor


Awarded, Cross Border Corporate and Strategic Acquisition of the Year
by M&A Advisor

Awarded, Cross Border M&A Deal of the Year
by M&A Advisor

Awarded, Deal of the Year
by ACG Detroit

Contact Info

PMCF | INVESTMENT
BANKING



DETROIT

2 Towne Square
Suite 425
Southfield, MI 48076
Phone: 248.223.3300



CHICAGO

120 S. Riverside Plaza
Suite 2100
Chicago, Illinois 60606
Phone: 312.602.3600



DENVER

8181 E. Tufts Avenue
Suite 600
Denver, CO 80237
Phone: 720.370.8181

2 Towne Square
Suite 425
Southfield, MI 48076

Experienced Professionals. Trusted Advisors. Proven Results.

This market overview is not an offer to sell or a solicitation of an offer to buy any security. It is not intended to be directed to investors as a basis for making an investment decision. This market overview does not rate or recommend securities of individual companies, nor does it contain sufficient information upon which to make an investment decision.

P&M Corporate Finance, LLC will seek to provide investment banking and/or other services to one or more of the companies mentioned in this market overview.

P&M Corporate Finance, LLC, and/or the analysts who prepared this market update, may own securities of one or more of the companies mentioned in this market overview.

The information provided in this market overview was obtained from sources believed to be reliable, but its accuracy cannot be guaranteed. It is not to be construed as legal, accounting, financial, or investment advice. Information, opinions, and estimates reflect P&M Corporate Finance,

LLC's judgment as of the date of publication and are subject to change without notice. P&M Corporate Finance, LLC undertakes no obligation to notify any recipient of this market overview of any such change.

The charts and graphs used in this market overview have been compiled by P&M Corporate Finance, LLC solely for illustrative purposes. All charts are as of the date of issuance of this market overview, unless otherwise noted.

The PMCF Medical Technology Indices may not be inclusive of all companies in the medical technology industry and is not a composite index of the medical technology industry sector returns. Index and sector returns are past performance which is not an indicator of future results.

This market overview is not directed to, or intended for distribution to, any person in any jurisdiction where such distribution would be contrary to law or regulation, or which would subject P&M Corporate Finance, LLC to licensing or registration requirements in such jurisdiction.

For more information, check out our new website, where you can access the electronic version of this report, sign up for future emails, read our latest industry reports, and more!

